They have developed a tailored product for their chip. Yes, it will need some more testing and refining but certainly saves time than the alternative approach of looking to find partners at this stage. Looks to me that they have the know how to develop pathogen detection.
The Company has successfully developed its first biochemical reactions for the detection and quantification of nucleic acid sequences (both DNA and RNA), for potential use and application at room temperature in its biochip technology. The nucleic acid sequences of interest could potentially be of viral, bacterial, or other microbial origin, which would allow for the development of Archer’s biochip towards tailored on-chip pathogen detection.
AXE Price at posting:
$1.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)